Publication:
Impact of systemic inflammatory markers in patients with alk -positive non-small cell lung cancer treated with crizotinib

dc.contributor.authorÖlmez, O. F.
dc.contributor.authorBilici, A.
dc.contributor.authorGürsoy, P.
dc.contributor.authorSakin, A.
dc.contributor.authorKorkmaz, T.
dc.contributor.authorÇil, I.
dc.contributor.authorÇakar, B.
dc.contributor.authorMenekse, S.
dc.contributor.authorDemir, T.
dc.contributor.authorAcıkgöz, O.
dc.contributor.authorHamdard, J.
dc.contributor.buuauthorÇubukcu, Erdem
dc.contributor.buuauthorÇUBUKÇU, ERDEM
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.
dc.date.accessioned2024-10-08T05:16:58Z
dc.date.available2024-10-08T05:16:58Z
dc.date.issued2023-11-01
dc.description.abstractObjectives: To evaluate the prognostic utility of inflammation-based prognostic scores in patients with ALK-positive metastatic or non-resectable non-small-cell lung cancer (NSCLC) treated with crizotinib.Patients and Methods: A total of 82 patients with ALK-positive metastatic or non-resectable NSCLC who received ALK TKI crizotinib were included. Pre-treatment modified Glasgow prognostic score (mGPS), prognostic nutritional index (PNI), and systemic immune-inflammation index (SII) were calculated. Multivariable logistic regression and Cox proportional hazards models were used to assess the impact of pretreatment mGPS, PNI, and SII on overall survival (OS), progression-free survival (PFS), and objective response rate (ORR).Results: The ORR was 77.2%, while 1-year OS and PFS rates were 95.0% and 93.5%, respectively. The univariate analysis revealed significantly higher 1-year PFS (89.4 vs. 64.4%, p=0.043) and OS (92.0 vs. 83.3%, p=0.01) rates in patients with low (<934.7) vs. high (>= 934.7) SII scores. Multivariate analysis revealed that PNI >= 0.09 was a significant determinant of poorer 1-year OS rates (hazard ratio [HR]: 2.46, 95% confidence interval [CI] 0.88-4.85, p=0.035). No significant difference was observed in survival rates according to gender, age, smoking status, prior lines of therapy, or mGPS scores, while higher mGPS scores (odds ratio [OR]: 0.1, 95%CI 0.16-1.04; p=0.009) and higher PNI scores (OR: 0.16, 95% CI 0.02-0.55; p=0.035) were associated with poorer ORR.Conclusion: Our findings indicate the prognostic significance of PNI and SII in terms of survival outcome and the impact of mGPS and PNI on treatment response in patients with ALK-positive NSCLC treated with crizotinib.
dc.identifier.doi10.1016/j.pulmoe.2022.11.006
dc.identifier.endpage485
dc.identifier.issn2531-0437
dc.identifier.issue6
dc.identifier.startpage478
dc.identifier.urihttps://doi.org/10.1016/j.pulmoe.2022.11.006
dc.identifier.urihttps://hdl.handle.net/11452/46011
dc.identifier.volume29
dc.identifier.wos001110055900001
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherElsevier
dc.relation.journalPulmonology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.subjectPrognostic nutritional index
dc.subjectPredicting prognosis
dc.subjectLymphocyte ratio
dc.subjectStage-i
dc.subjectChemotherapy
dc.subjectSurvival
dc.subjectProgression
dc.subjectDocetaxel
dc.subjectOutcomes
dc.subjectScores
dc.subjectNsclc
dc.subjectAlk-positive
dc.subjectInflammation-based prognostic scores
dc.subjectTreatment response
dc.subjectSurvival
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectRespiratory system
dc.titleImpact of systemic inflammatory markers in patients with alk -positive non-small cell lung cancer treated with crizotinib
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublicationf971677f-09c5-4463-bf01-3c6341fbe5f7
relation.isAuthorOfPublication.latestForDiscoveryf971677f-09c5-4463-bf01-3c6341fbe5f7

Files

Collections